Predictive Factors of Response to Liraglutide in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Oct 21

PMID 39429734

Authors

Jinfang Song

Na Li

Yongru Zhuang

Ya Chen

Chu Zhang

Jian Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Although liraglutide has established advantages in treating patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), there are still some patients with lower responsiveness to liraglutide. The objective of the study was to identify the predictors of response to liraglutide in patients with T2DM and MS.

Methods: This retrospective cohort study included patients diagnosed with T2DM and MS who received liraglutide treatment as a part of their diabetes management for a minimum of six months. The participants were stratified into two groups: responders (HbA1c reduction≥1.0% and weight loss≥3%) and non-responders. The discrepancies in baseline data between the two groups were analyzed, containing comedications, test parameters, and basic profiles. The affecting factors of response to liraglutide by Logistic regression analysis were performed, and the predictive ability of the identified factors was evaluated by plotting a receiver operating characteristic (ROC) curve.

Results: A total of 417 patients with T2DM and MS were examined and followed up according to the inclusion criteria, and 206 patients completed the follow-up; 105 (50.97%) were responders and 101 (49.03%) were non-responders to liraglutide. The binary logistic regression analysis identified baseline HbA1c, baseline BMI, and the duration of T2DM as significant predictors of glycemic and weight responses to liraglutide (0.05). The area under the curve of the ROC for the three predictors of liraglutide response after 6 months of treatment was 0.851 (95% confidence interval: 0.793 - 0.910).

Conclusion: The baseline HbA1c, baseline BMI, and duration of T2DM were shown to be predictive factors of glycemic and weight improvements in patients with T2DM and MS treated with liraglutide, and had good predictive power.

References

Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E . Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017; 54(12):1101-1114. DOI: 10.1007/s00592-017-1054-2. View

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

Haraguchi A, Fujishima K, Ando T, Mori F, Imaizumi M, Abiru N . Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide. Minerva Endocrinol. 2014; 39(4):289-97. View

Saraiva F, Sposito A . Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014; 13:142. PMC: 4216654. DOI: 10.1186/s12933-014-0142-7. View

Jones A, McDonald T, Shields B, Hill A, Hyde C, Knight B . Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2015; 39(2):250-7. PMC: 4894547. DOI: 10.2337/dc15-0258. View

Ji L, Lu J, Guo X, Yang W, Weng J, Jia W . Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013; 13:602. PMC: 3729491. DOI: 10.1186/1471-2458-13-602. View

Cowie C . Diabetes Diagnosis and Control: Missed Opportunities to Improve Health : The 2018 Kelly West Award Lecture. Diabetes Care. 2019; 42(6):994-1004. PMC: 6609950. DOI: 10.2337/dci18-0047. View

Dai M, Dai S, Gu L, Xiang Z, Xu A, Lu S . Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials. J Clin Res Pediatr Endocrinol. 2024; 16(3):323-333. PMC: 11590762. DOI: 10.4274/jcrpe.galenos.2024.2024-1-5. View

Babenko A, Savitskaya D, Kononova Y, Trofimova A, Simanenkova A, Vasilyeva E . Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. J Diabetes Res. 2019; 2019:1365162. PMC: 6421820. DOI: 10.1155/2019/1365162. View

10.

Feng P, Yu D, Chen L, Chang B, Ji Q, Li S . Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin. 2015; 36(2):200-8. PMC: 4326793. DOI: 10.1038/aps.2014.136. View

11.

Cornell S . A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. J Clin Pharm Ther. 2013; 38(3):181-9. DOI: 10.1111/jcpt.12040. View

12.

Cefalu W, Stenlof K, Leiter L, Wilding J, Blonde L, Polidori D . Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015; 58(6):1183-7. PMC: 4800739. DOI: 10.1007/s00125-015-3547-2. View

13.

Simioni N, Berra C, Boemi M, Bossi A, Candido R, Di Cianni G . Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. Acta Diabetol. 2018; 55(6):557-568. PMC: 5959971. DOI: 10.1007/s00592-018-1124-0. View

14.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

15.

Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N . Comment on: American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34(Suppl. 1):S11-S61. Diabetes Care. 2011; 34(5):e53. PMC: 3114493. DOI: 10.2337/dc11-0174. View

16.

Campbell J, Drucker D . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6):819-837. DOI: 10.1016/j.cmet.2013.04.008. View

17.

Zhang L, Yu W, Zhu H, Li H, Qiao J . Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. World J Clin Cases. 2022; 10(21):7495-7501. PMC: 9353915. DOI: 10.12998/wjcc.v10.i21.7495. View

18.

Kong X, Xing X, Hong J, Zhang X, Yang W . Association of a type 2 diabetes genetic risk score with insulin secretion modulated by insulin sensitivity among Chinese Hans. Clin Genet. 2016; 91(6):832-842. PMC: 5148717. DOI: 10.1111/cge.12817. View

19.

Wang T, Zhang F, Wang X, Li X, Ling H, Lv D . Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2020; 45(5):1050-1057. DOI: 10.1111/jcpt.13134. View

20.

Mogre V, Salifu Z, Abedandi R . Prevalence, components and associated demographic and lifestyle factors of the metabolic syndrome in type 2 diabetes mellitus. J Diabetes Metab Disord. 2014; 13:80. PMC: 4106220. DOI: 10.1186/2251-6581-13-80. View